Correlation of ADC With Pathological Treatment Response for Radiation Therapy of Pancreatic Cancer

Entesar Dalah, Beth Erickson, Kiyoko Oshima, Diane Schott, William A. Hall, Eric Paulson, An Tai, Paul Knechtges, X. Allen Li

Research output: Contribution to journalArticle

Abstract

PURPOSE: To investigate the feasibility of using apparent diffusion coefficient (ADC) to assesspathological treatment response in pancreatic ductal adenocarcinoma (PDAC) following neoadjuvant chemoradiation (nCR). MATERIALS/METHODS: MRI and pathological data collected for 25patients with resectable and borderline resectable PDAC following nCR were retrospectively analyzed. Pre- and post-nCR mean ADC values in the tumors were compared using Wilcoxon matched pairs test. Correlation of pathological treatment response and ADC values was assessed using Pearson's correlation coefficient test and receiver-operating-curve (ROC) analysis. RESULTS: The average mean and standard deviation (SD) of the ADC values for all the patients analyzed were significantly higher in post-nCR (1.667±0.161×10-3) compared with those prior to nCR (1.395±0.136×10-3 mm2/sec), (P<0.05). The mean ADC values after nCR were significantly correlated with the pathological responses (r=-0.5172); P=0.02. The area under the curve (AUC) of the ADC values for differentiating G1, G2 and G3 pathological responses, using ROC analysis, was found to be 0.6310 and P=0.03. CONCLUSION: Changes of pre- and post-treatment ADC values significantly correlated with pathological treatment response for PDAC patients treated with chemoradiation therapy, indicating that the ADC could be used to assesstreatment response for PDAC.

Original languageEnglish (US)
Pages (from-to)391-398
Number of pages8
JournalTranslational Oncology
Volume11
Issue number2
DOIs
StatePublished - Apr 1 2018
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Radiotherapy
Adenocarcinoma
Therapeutics
Area Under Curve
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Correlation of ADC With Pathological Treatment Response for Radiation Therapy of Pancreatic Cancer. / Dalah, Entesar; Erickson, Beth; Oshima, Kiyoko; Schott, Diane; Hall, William A.; Paulson, Eric; Tai, An; Knechtges, Paul; Li, X. Allen.

In: Translational Oncology, Vol. 11, No. 2, 01.04.2018, p. 391-398.

Research output: Contribution to journalArticle

Dalah, E, Erickson, B, Oshima, K, Schott, D, Hall, WA, Paulson, E, Tai, A, Knechtges, P & Li, XA 2018, 'Correlation of ADC With Pathological Treatment Response for Radiation Therapy of Pancreatic Cancer', Translational Oncology, vol. 11, no. 2, pp. 391-398. https://doi.org/10.1016/j.tranon.2018.01.018
Dalah, Entesar ; Erickson, Beth ; Oshima, Kiyoko ; Schott, Diane ; Hall, William A. ; Paulson, Eric ; Tai, An ; Knechtges, Paul ; Li, X. Allen. / Correlation of ADC With Pathological Treatment Response for Radiation Therapy of Pancreatic Cancer. In: Translational Oncology. 2018 ; Vol. 11, No. 2. pp. 391-398.
@article{6a751736feba442998cde371d28c7e40,
title = "Correlation of ADC With Pathological Treatment Response for Radiation Therapy of Pancreatic Cancer",
abstract = "PURPOSE: To investigate the feasibility of using apparent diffusion coefficient (ADC) to assesspathological treatment response in pancreatic ductal adenocarcinoma (PDAC) following neoadjuvant chemoradiation (nCR). MATERIALS/METHODS: MRI and pathological data collected for 25patients with resectable and borderline resectable PDAC following nCR were retrospectively analyzed. Pre- and post-nCR mean ADC values in the tumors were compared using Wilcoxon matched pairs test. Correlation of pathological treatment response and ADC values was assessed using Pearson's correlation coefficient test and receiver-operating-curve (ROC) analysis. RESULTS: The average mean and standard deviation (SD) of the ADC values for all the patients analyzed were significantly higher in post-nCR (1.667±0.161×10-3) compared with those prior to nCR (1.395±0.136×10-3 mm2/sec), (P<0.05). The mean ADC values after nCR were significantly correlated with the pathological responses (r=-0.5172); P=0.02. The area under the curve (AUC) of the ADC values for differentiating G1, G2 and G3 pathological responses, using ROC analysis, was found to be 0.6310 and P=0.03. CONCLUSION: Changes of pre- and post-treatment ADC values significantly correlated with pathological treatment response for PDAC patients treated with chemoradiation therapy, indicating that the ADC could be used to assesstreatment response for PDAC.",
author = "Entesar Dalah and Beth Erickson and Kiyoko Oshima and Diane Schott and Hall, {William A.} and Eric Paulson and An Tai and Paul Knechtges and Li, {X. Allen}",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.tranon.2018.01.018",
language = "English (US)",
volume = "11",
pages = "391--398",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "2",

}

TY - JOUR

T1 - Correlation of ADC With Pathological Treatment Response for Radiation Therapy of Pancreatic Cancer

AU - Dalah, Entesar

AU - Erickson, Beth

AU - Oshima, Kiyoko

AU - Schott, Diane

AU - Hall, William A.

AU - Paulson, Eric

AU - Tai, An

AU - Knechtges, Paul

AU - Li, X. Allen

PY - 2018/4/1

Y1 - 2018/4/1

N2 - PURPOSE: To investigate the feasibility of using apparent diffusion coefficient (ADC) to assesspathological treatment response in pancreatic ductal adenocarcinoma (PDAC) following neoadjuvant chemoradiation (nCR). MATERIALS/METHODS: MRI and pathological data collected for 25patients with resectable and borderline resectable PDAC following nCR were retrospectively analyzed. Pre- and post-nCR mean ADC values in the tumors were compared using Wilcoxon matched pairs test. Correlation of pathological treatment response and ADC values was assessed using Pearson's correlation coefficient test and receiver-operating-curve (ROC) analysis. RESULTS: The average mean and standard deviation (SD) of the ADC values for all the patients analyzed were significantly higher in post-nCR (1.667±0.161×10-3) compared with those prior to nCR (1.395±0.136×10-3 mm2/sec), (P<0.05). The mean ADC values after nCR were significantly correlated with the pathological responses (r=-0.5172); P=0.02. The area under the curve (AUC) of the ADC values for differentiating G1, G2 and G3 pathological responses, using ROC analysis, was found to be 0.6310 and P=0.03. CONCLUSION: Changes of pre- and post-treatment ADC values significantly correlated with pathological treatment response for PDAC patients treated with chemoradiation therapy, indicating that the ADC could be used to assesstreatment response for PDAC.

AB - PURPOSE: To investigate the feasibility of using apparent diffusion coefficient (ADC) to assesspathological treatment response in pancreatic ductal adenocarcinoma (PDAC) following neoadjuvant chemoradiation (nCR). MATERIALS/METHODS: MRI and pathological data collected for 25patients with resectable and borderline resectable PDAC following nCR were retrospectively analyzed. Pre- and post-nCR mean ADC values in the tumors were compared using Wilcoxon matched pairs test. Correlation of pathological treatment response and ADC values was assessed using Pearson's correlation coefficient test and receiver-operating-curve (ROC) analysis. RESULTS: The average mean and standard deviation (SD) of the ADC values for all the patients analyzed were significantly higher in post-nCR (1.667±0.161×10-3) compared with those prior to nCR (1.395±0.136×10-3 mm2/sec), (P<0.05). The mean ADC values after nCR were significantly correlated with the pathological responses (r=-0.5172); P=0.02. The area under the curve (AUC) of the ADC values for differentiating G1, G2 and G3 pathological responses, using ROC analysis, was found to be 0.6310 and P=0.03. CONCLUSION: Changes of pre- and post-treatment ADC values significantly correlated with pathological treatment response for PDAC patients treated with chemoradiation therapy, indicating that the ADC could be used to assesstreatment response for PDAC.

UR - http://www.scopus.com/inward/record.url?scp=85044783020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044783020&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2018.01.018

DO - 10.1016/j.tranon.2018.01.018

M3 - Article

VL - 11

SP - 391

EP - 398

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 2

ER -